“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

An existing oral drug already used to treat lung cancer could help improve survival rates for bladder cancer patients, a new clinical trial by UK scientists has found. There are approximately 10,300 ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

Patients with advanced bladder cancer have significantly less risk of the disease progressing or returning when treated with an immunotherapy drug called durvalumab, research has shown. Jörg ...

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

Squamous cell carcinoma of the bladder is rare, accounting for 2% to 5% of bladder cancers in the U.S., and is linked to chronic bladder irritation. Diagnosis involves cystoscopy, biopsy, and imaging ...

N1 Single lymph node metastasis, 2 cm or less in greatest dimension N1 Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac or presacral lymph node) N2 ...